For centuries, losing a tooth meant relying on dentures, bridges, or implants. But groundbreaking research from Japan is challenging that reality. Scientists are developing a simple drug — often called the “tooth regeneration shot” — that could stimulate the growth of new teeth from within the body. While it’s not available yet, human trials are progressing, and the potential impact on dentistry could be revolutionary.
The Biological Breakthrough: Awakening Dormant Tooth Buds
Humans normally develop two sets of teeth: baby teeth and permanent adult teeth. However, research has revealed that we possess the remnants of a potential third set — dormant tooth buds suppressed by a specific protein.
This protein, known as USAG-1 (uterine sensitization-associated gene-1), acts as a molecular brake on tooth development by inhibiting key signaling pathways like BMP (bone morphogenetic protein). By blocking USAG-1, researchers can reactivate these natural growth signals.
The leading candidate is TRG-035, a monoclonal antibody developed by Toregem BioPharma, a spin-off from Kyoto University. Led by Dr. Katsu Takahashi, the team created this drug to neutralize USAG-1, allowing new teeth to form using the patient’s own tissues without needing stem cell transplants or artificial scaffolds.
Proven in Animals, Now Testing in Humans
The approach has shown strong results in animal studies. In mice and ferrets (whose dental structure is closer to humans), a single dose triggered the growth of fully formed new teeth with proper enamel, dentin, pulp, and roots. Importantly, the new teeth emerged in the correct locations with no major side effects observed.
Human trials began in late 2024 at Kyoto University Hospital. The Phase 1 study involved around 30 healthy adult men (aged 30-64) missing at least one tooth. Participants received intravenous doses focused primarily on safety and dosing. Early reports indicate no serious side effects, and the initial safety phase has largely wrapped up successfully as of early 2026.
In May 2026, Toregem BioPharma raised approximately $5.3 million to advance to Phase 2 trials. These next steps will target children aged 2-7 with congenital tooth agenesis (born missing multiple teeth due to conditions like hypodontia or oligodontia). Future phases may expand to adults with age-related or injury-related tooth loss, with plans for U.S. trials as well.
Expected Timeline and Remaining Challenges
If all goes well, the treatment could reach the market around 2030, initially for those with congenital tooth defects before broader applications. This would mark the world’s first drug capable of regenerating natural teeth.
That said, significant hurdles remain:
- Ensuring new teeth grow in the right position, size, and alignment.
- Confirming long-term durability and functionality.
- Monitoring for any off-target effects, since USAG-1 plays roles beyond teeth.
- Proving consistent efficacy in larger human populations.
No full efficacy results from humans have been published yet — success in animals doesn’t always translate perfectly to people.
Why This Could Transform Lives
Tooth loss affects millions, impacting nutrition, speech, self-confidence, and even overall health (including links to heart disease). Current solutions like implants are effective but expensive, invasive, and not suitable for everyone — especially children or those with certain medical conditions.
A regenerative “shot” could offer a far more natural, biological solution. It represents a shift from replacement to true regeneration in medicine.
The Road Ahead
While we’re still in the early stages, this Japanese innovation is one of the most promising developments in regenerative dentistry. Ongoing research into stem cells, tissue engineering, and other methods continues in parallel, but the USAG-1 antibody stands out for its relative simplicity.
For now, the best advice remains prevention: maintain excellent oral hygiene, regular dental check-ups, and a tooth-friendly diet. But for the millions living with missing teeth or congenital conditions, the tooth fairy might soon have some serious scientific competition.
Keep an eye on updates from Toregem BioPharma and clinical trial registries. The future of smiles could look very different in the coming decade.
About The Author
